PLRX Stock Overview A clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Pliant Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Pliant Therapeutics Historical stock prices Current Share Price US$10.75 52 Week High US$18.30 52 Week Low US$10.22 Beta 1.06 1 Month Change -18.38% 3 Month Change -25.96% 1 Year Change -38.22% 3 Year Change 1.90% 5 Year Change n/a Change since IPO -49.53%
Recent News & Updates See more updates
Pliant Therapeutics, Inc. Appoints Delphine Imbert as Chief Technical Officer Jan 22
Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry? Jan 02
New major risk - Revenue and earnings growth Nov 15
New major risk - Revenue and earnings growth Nov 12
Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs Oct 02
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt? Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching Sep 11
New major risk - Revenue and earnings growth Aug 09
New minor risk - Shareholder dilution Aug 08
Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Jul 15
Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index Jul 03
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors Jun 15
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package? Jun 07
Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis May 15
First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023) May 07
Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 23
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis Mar 13
New major risk - Revenue and earnings growth Mar 08
Consensus revenue estimates decrease by 69%, EPS upgraded Mar 05
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 28
Price target decreased by 7.1% to US$42.67 Feb 28
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load? Feb 27
Price target decreased by 9.4% to US$44.08 Feb 05
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Feb 05
Consensus revenue estimates decrease by 20%, EPS upgraded Nov 16
Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022) Nov 10
Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer Oct 17
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Sep 27
Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer Sep 16
Consensus revenue estimates fall by 32% Aug 16
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 10
Chief Business Officer notifies of intention to sell stock Aug 06
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly? Jul 21
Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress Jun 24
Consensus revenue estimates increase by 11% May 21
Consensus revenue estimates increase by 123%, EPS downgraded May 16
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat May 11
General Counsel & Corporate Secretary notifies of intention to sell stock Apr 08
Consensus revenue estimates decrease by 29%, EPS upgraded Mar 16
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt? Mar 13
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 11
Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors Feb 03
President notifies of intention to sell stock Jan 27 Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer
Price target increased by 17% to US$49.09 Jan 24
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Jan 23
President notifies of intention to sell stock Jan 08
Insufficient new directors Jan 01
General Counsel & Corporate Secretary notifies of intention to sell stock Dec 27
Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis Dec 16
Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics Nov 19
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 11
President exercised options and sold US$256k worth of stock Sep 16
Pliant Therapeutics Appoints Katharine Knobi to Board of Directors Sep 16
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load? Sep 10
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis Sep 02
Pliant Therapeutics: Wait For A Better Price To Get In Aug 20
Consensus revenue estimates increase by 48% Aug 15
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 10
Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M Aug 08
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans? Jul 28
Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis Jul 22
Pliant's PLN-74809 gets FDA fast track status for liver disease Jul 21
Price target increased to US$43.71 Jul 12
Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals Jul 11
Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis Jul 11 Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies Jun 23
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration Jun 17
Pliant: Major Catalyst Expected Beginning Of 2023 Jun 03
Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference May 19
Price target decreased to US$39.67 May 18
Consensus forecasts updated May 16
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 10
Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022 May 02
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate Apr 22
Consensus forecasts updated Mar 08
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 03
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers Mar 01
Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis Feb 25
Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones Jan 13
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation Dec 29
Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020) Nov 11
Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis Sep 08
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth Sep 07
Consensus forecasts updated Aug 17
Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020) Aug 11
President notifies of intention to sell stock Jun 17
Consensus revenue estimates fall to US$11.8m May 18
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12% May 17
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates May 13
First quarter 2021 earnings released: US$0.64 loss per share (vs US$5.89 profit in 1Q 2020) May 12
President exercised options and sold US$99k worth of stock Apr 17
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans Mar 22
President notifies of intention to sell stock Mar 19
Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner Mar 17
Investor sentiment improved over the past week Mar 12 Shareholder Returns PLRX US Pharmaceuticals US Market 7D -1.6% 2.3% -0.9% 1Y -38.2% 4.3% 22.6%
See full shareholder returns
Return vs Market: PLRX underperformed the US Market which returned 24.3% over the past year.
Price Volatility Is PLRX's price volatile compared to industry and market? PLRX volatility PLRX Average Weekly Movement 8.6% Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: PLRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PLRX's weekly volatility (9%) has been stable over the past year.
About the Company Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.
Show more Pliant Therapeutics, Inc. Fundamentals Summary How do Pliant Therapeutics's earnings and revenue compare to its market cap? PLRX fundamental statistics Market cap US$648.70m Earnings (TTM ) -US$201.68m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PLRX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$201.68m Earnings -US$201.68m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 06:01 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pliant Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Nash Canaccord Genuity Pete Stavropoulos Cantor Fitzgerald & Co. David Lebowitz Citigroup Inc
Show 14 more analysts 
